Leo Pharma: Approval opens up a huge market
US approval of a new indication for a gel product opens up an extremely interesting market for the Danish company Leo Pharma.
“With this product and our solar keratosis product Picato, which we launched on the US market earlier this year, we find ourselves in a situation where a new market has opened up, which is actually bigger than our total market so far,” says Jacob Anker Rasmussen, VP of Global Sales and Marketing in Leo Pharma.
Allerede abonnent?Log ind her
Læs hele artiklen
Få adgang i 14 dage for 0 kr. Det kræver intet kreditkort, og du vil ikke overgå til et betalt abonnement efterfølgende.
Med din prøveperiode får du:
Få fuld adgang til dig og dine kollegaer
Start et gratis virksomhedsprøveabonnementRelaterede artikler
Leo Pharma: A strategy for each country
For abonnenter
